| Auburn Family Health Center Pc | |
|
2115 14th Street Suite 100 Auburn NE 68305-1797 | |
| (402) 274-4993 | |
| (402) 274-4905 |
| Full Name | Auburn Family Health Center Pc |
|---|---|
| Speciality | Family Medicine |
| Location | 2115 14th Street, Auburn, Nebraska |
| Authorized Official Name and Position | Gary R Ensz (PRESIDENT) |
| Authorized Official Contact | 4022744993 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Auburn Family Health Center Pc 2115 14th Street Suite 100 Auburn NE 68305-1797 Ph: (402) 274-4993 | Auburn Family Health Center Pc 2115 14th Street Suite 100 Auburn NE 68305-1797 Ph: (402) 274-4993 |
| NPI Number | 1821169459 |
|---|---|
| Provider Enumeration Date | 11/13/2006 |
| Last Update Date | 10/16/2019 |
| Medicare PECOS PAC ID | 4385749191 |
|---|---|
| Medicare Enrollment ID | O20070423000350 |
News Archive
Nektar Therapeutics today announced that new Phase 2 clinical data for NKTR-102, Nektar's lead oncology candidate being evaluated in multiple cancer indications, have been selected for presentation at the 47th Annual Meeting of the American Society of Clinical Oncology being held June 3-7, 2011 in Chicago, Illinois.
Mobile devices are everywhere and children are using them more frequently at young ages. The impact these mobile devices are having on the development and behavior of children is still relatively unknown. In a commentary in the journal Pediatrics, researchers review the many types of interactive media available today and raise important questions regarding their use as educational tools, as well as their potential detrimental role in stunting the development of important tools for self-regulation.
What to fear most if faced by a cancer diagnosis is the spread of the cancer to other parts of the body. This process called metastasis accounts for over 90% of cancer patient deaths and therefore is a strong focus for cancer researchers.
TearLab Corporation announced today that it is in receipt of a communication from the U.S. Food and Drug Administration indicating that the data submitted by the Company was not sufficient to gain approval of its CLIA Waiver categorization application for the TearLab Osmolarity System.
› Verified 5 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821169459 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | (* (Not Available)) | Primary |
| 207R00000X | Internal Medicine | (* (Not Available)) | Secondary |
| Provider Name | Michael L Zaruba |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1386749547 PECOS PAC ID: 2860444312 Enrollment ID: I20100709000477 |
News Archive
Nektar Therapeutics today announced that new Phase 2 clinical data for NKTR-102, Nektar's lead oncology candidate being evaluated in multiple cancer indications, have been selected for presentation at the 47th Annual Meeting of the American Society of Clinical Oncology being held June 3-7, 2011 in Chicago, Illinois.
Mobile devices are everywhere and children are using them more frequently at young ages. The impact these mobile devices are having on the development and behavior of children is still relatively unknown. In a commentary in the journal Pediatrics, researchers review the many types of interactive media available today and raise important questions regarding their use as educational tools, as well as their potential detrimental role in stunting the development of important tools for self-regulation.
What to fear most if faced by a cancer diagnosis is the spread of the cancer to other parts of the body. This process called metastasis accounts for over 90% of cancer patient deaths and therefore is a strong focus for cancer researchers.
TearLab Corporation announced today that it is in receipt of a communication from the U.S. Food and Drug Administration indicating that the data submitted by the Company was not sufficient to gain approval of its CLIA Waiver categorization application for the TearLab Osmolarity System.
› Verified 5 days ago
| Provider Name | Jeffery G Meade |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1366547523 PECOS PAC ID: 5395758767 Enrollment ID: I20100709000489 |
News Archive
Nektar Therapeutics today announced that new Phase 2 clinical data for NKTR-102, Nektar's lead oncology candidate being evaluated in multiple cancer indications, have been selected for presentation at the 47th Annual Meeting of the American Society of Clinical Oncology being held June 3-7, 2011 in Chicago, Illinois.
Mobile devices are everywhere and children are using them more frequently at young ages. The impact these mobile devices are having on the development and behavior of children is still relatively unknown. In a commentary in the journal Pediatrics, researchers review the many types of interactive media available today and raise important questions regarding their use as educational tools, as well as their potential detrimental role in stunting the development of important tools for self-regulation.
What to fear most if faced by a cancer diagnosis is the spread of the cancer to other parts of the body. This process called metastasis accounts for over 90% of cancer patient deaths and therefore is a strong focus for cancer researchers.
TearLab Corporation announced today that it is in receipt of a communication from the U.S. Food and Drug Administration indicating that the data submitted by the Company was not sufficient to gain approval of its CLIA Waiver categorization application for the TearLab Osmolarity System.
› Verified 5 days ago
| Provider Name | John A Gill |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1831294099 PECOS PAC ID: 4880790401 Enrollment ID: I20100709000571 |
News Archive
Nektar Therapeutics today announced that new Phase 2 clinical data for NKTR-102, Nektar's lead oncology candidate being evaluated in multiple cancer indications, have been selected for presentation at the 47th Annual Meeting of the American Society of Clinical Oncology being held June 3-7, 2011 in Chicago, Illinois.
Mobile devices are everywhere and children are using them more frequently at young ages. The impact these mobile devices are having on the development and behavior of children is still relatively unknown. In a commentary in the journal Pediatrics, researchers review the many types of interactive media available today and raise important questions regarding their use as educational tools, as well as their potential detrimental role in stunting the development of important tools for self-regulation.
What to fear most if faced by a cancer diagnosis is the spread of the cancer to other parts of the body. This process called metastasis accounts for over 90% of cancer patient deaths and therefore is a strong focus for cancer researchers.
TearLab Corporation announced today that it is in receipt of a communication from the U.S. Food and Drug Administration indicating that the data submitted by the Company was not sufficient to gain approval of its CLIA Waiver categorization application for the TearLab Osmolarity System.
› Verified 5 days ago
| Provider Name | Gary R Ensz |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1447355623 PECOS PAC ID: 2163528787 Enrollment ID: I20100709000626 |
News Archive
Nektar Therapeutics today announced that new Phase 2 clinical data for NKTR-102, Nektar's lead oncology candidate being evaluated in multiple cancer indications, have been selected for presentation at the 47th Annual Meeting of the American Society of Clinical Oncology being held June 3-7, 2011 in Chicago, Illinois.
Mobile devices are everywhere and children are using them more frequently at young ages. The impact these mobile devices are having on the development and behavior of children is still relatively unknown. In a commentary in the journal Pediatrics, researchers review the many types of interactive media available today and raise important questions regarding their use as educational tools, as well as their potential detrimental role in stunting the development of important tools for self-regulation.
What to fear most if faced by a cancer diagnosis is the spread of the cancer to other parts of the body. This process called metastasis accounts for over 90% of cancer patient deaths and therefore is a strong focus for cancer researchers.
TearLab Corporation announced today that it is in receipt of a communication from the U.S. Food and Drug Administration indicating that the data submitted by the Company was not sufficient to gain approval of its CLIA Waiver categorization application for the TearLab Osmolarity System.
› Verified 5 days ago
| Provider Name | Andrew C Ensz |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1417311457 PECOS PAC ID: 3870822547 Enrollment ID: I20190905000227 |
News Archive
Nektar Therapeutics today announced that new Phase 2 clinical data for NKTR-102, Nektar's lead oncology candidate being evaluated in multiple cancer indications, have been selected for presentation at the 47th Annual Meeting of the American Society of Clinical Oncology being held June 3-7, 2011 in Chicago, Illinois.
Mobile devices are everywhere and children are using them more frequently at young ages. The impact these mobile devices are having on the development and behavior of children is still relatively unknown. In a commentary in the journal Pediatrics, researchers review the many types of interactive media available today and raise important questions regarding their use as educational tools, as well as their potential detrimental role in stunting the development of important tools for self-regulation.
What to fear most if faced by a cancer diagnosis is the spread of the cancer to other parts of the body. This process called metastasis accounts for over 90% of cancer patient deaths and therefore is a strong focus for cancer researchers.
TearLab Corporation announced today that it is in receipt of a communication from the U.S. Food and Drug Administration indicating that the data submitted by the Company was not sufficient to gain approval of its CLIA Waiver categorization application for the TearLab Osmolarity System.
› Verified 5 days ago
| Provider Name | Amanda Louise Ensz |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1164840286 PECOS PAC ID: 6002183159 Enrollment ID: I20191025000797 |
News Archive
Nektar Therapeutics today announced that new Phase 2 clinical data for NKTR-102, Nektar's lead oncology candidate being evaluated in multiple cancer indications, have been selected for presentation at the 47th Annual Meeting of the American Society of Clinical Oncology being held June 3-7, 2011 in Chicago, Illinois.
Mobile devices are everywhere and children are using them more frequently at young ages. The impact these mobile devices are having on the development and behavior of children is still relatively unknown. In a commentary in the journal Pediatrics, researchers review the many types of interactive media available today and raise important questions regarding their use as educational tools, as well as their potential detrimental role in stunting the development of important tools for self-regulation.
What to fear most if faced by a cancer diagnosis is the spread of the cancer to other parts of the body. This process called metastasis accounts for over 90% of cancer patient deaths and therefore is a strong focus for cancer researchers.
TearLab Corporation announced today that it is in receipt of a communication from the U.S. Food and Drug Administration indicating that the data submitted by the Company was not sufficient to gain approval of its CLIA Waiver categorization application for the TearLab Osmolarity System.
› Verified 5 days ago
News Archive
Nektar Therapeutics today announced that new Phase 2 clinical data for NKTR-102, Nektar's lead oncology candidate being evaluated in multiple cancer indications, have been selected for presentation at the 47th Annual Meeting of the American Society of Clinical Oncology being held June 3-7, 2011 in Chicago, Illinois.
Mobile devices are everywhere and children are using them more frequently at young ages. The impact these mobile devices are having on the development and behavior of children is still relatively unknown. In a commentary in the journal Pediatrics, researchers review the many types of interactive media available today and raise important questions regarding their use as educational tools, as well as their potential detrimental role in stunting the development of important tools for self-regulation.
What to fear most if faced by a cancer diagnosis is the spread of the cancer to other parts of the body. This process called metastasis accounts for over 90% of cancer patient deaths and therefore is a strong focus for cancer researchers.
TearLab Corporation announced today that it is in receipt of a communication from the U.S. Food and Drug Administration indicating that the data submitted by the Company was not sufficient to gain approval of its CLIA Waiver categorization application for the TearLab Osmolarity System.
› Verified 5 days ago
Auburn Family Health Center Pc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2115 14th St Ste 100, Auburn, NE 68305 Phone: 402-274-4993 Fax: 402-274-4905 |